FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin Forbes In SHARP, VYTORIN 10/20 mg lowered LDL cholesterol in patients with moderate to severe chronic kidney disease (CKD), and major vascular events were reduced in the treatment group compared to placebo. The trial therefore demonstrated that treatment with ... FDA fails to approve cholesterol drug for kidney disease FDA Turns Down Expanded Use of Merck's Vytorin and Zetia Vytorin US label updated with SHARP results |
